



Oncomine Clinical Research Grant Program

Together, let's help shape the future
of precision medicine

Thermo Fisher Scientific values and supports independent research to promote excellence in molecular profiling

The Oncomine Clinical Research Grant Program supports investigator-initiated studies (IIS) and education projects in oncology research, with the goal to increase high-quality molecular profiling and to help democratize access to sequencing technologies.



Our global network of awardees of the Oncomine Clinical Research Grant

Since the program's inception in 2020, the Oncomine Clinical Research Grant Program has awarded up to \$200,000 in reagents and general funding for 37 unique research projects conducted by independent clinical research teams. Grants have been presented to laboratories from 18 different countries across five continents. Previously supported projects have focused on many different aspects of clinical cancer research, with topics in solid tumor, pediatric oncology, hemato-oncology, immuno-oncology, and liquid biopsy research.



Distribution of the awardees of the Oncomine Clinical Research Grant.

From the awardees



“The Oncomine grant program gives a chance to those who wouldn’t otherwise have it to be able to work with next-generation sequencing technologies. The funding from the Oncomine grant program can really help us overcome one of the biggest hurdles for smaller and less funded centers to be able to work with these types of emerging technologies.”

—**Brandon Sheffield, MD**

William Osler Health System, Canada

2020 awardee of the Oncomine Clinical Research Grant




“Industry funding [like the Oncomine Clinical Research Grant Program] is important because it can generate a sort of virtual circle, creating a link between the industry and different academic institutions and hospital research labs, and this link can foster the development and the implementation of new platforms or new assays focused on the unmet clinical needs of the future.”

—**Elena Guerini Rocco, MD**

European Institute of Oncology IRCCS, Italy

2021 awardee of the Oncomine Clinical Research Grant



“The opportunity the Oncomine grant has afforded us to work on the analysis of the T cell repertoire has also opened a number of opportunities for my team to collaborate on larger studies. We are now moving from the analysis that we have done with the Oncomine grant to a large study at the national level to further evaluate these biomarkers and the T cell repertoire.”

—**Elin Gray, PhD**

Edith Cowan University, Australia

2021 awardee of the Oncomine Clinical Research Grant



“The OCRG program is a fantastic way of actually starting something, then making sure it works and convincing everyone, and it is a first step toward new solutions and new ideas.”

—**Fernando López-Ríos, MD, PhD**

Chief of the Pathology Section, Head of the Molecular Diagnostics Service


12 de Octubre University Hospital, Madrid

2021 Awardee of the Oncomine Clinical Research Grant

Overview of awarded grants

The Oncomine Clinical Research Grant Program continues to grow as a global platform for scientific collaboration, having received more than 550 applications from 67 countries across 6 continents.

To date, 37 grants have been awarded across 18 countries and 5 continents, involving 56 principal and co-principal investigators, **distributed across different global regions**, with the highest number in Europe, the Middle East, and Africa (EMEA), followed by North America (NA), Asia Pacific and Japan (APJ), and one in Latin America (LATAM).





Overview of supported projects

The supported projects have generated valuable scientific outcomes and play a key role in advancing clinical oncology research, while expanding access to NGS using **Ion Torrent™ Oncomine™ assays**.


The grant program demonstrates its **commitment to nurturing talent at various career stages by supporting a balanced group of investigators**, including 30 established researchers and 26 early-career researchers.

Oncomine Clinical Research Grant Program–funded projects are conducted in both leading academic institutions and community hospitals, with 22 projects based in academic centers and 15 in community hospitals. This demonstrates the program’s commitment to fostering high-quality genomic testing across diverse health care environments.



With more than **\$5.5 million** awarded to date, the program continues to drive innovation in precision **oncology**, helping ensure that, regardless of location or health care setting, there is accessibility to the most advanced diagnostic tools.

The majority of the projects focused on studying solid tumors (76%), with lung cancer and gynecological cancers representing the largest areas of focus. Hematological tumors accounted for 24% of the grants, with the primary focus on myeloid neoplasms.



Application process

The evaluation process is performed by a committee of external experts in the field, along with Thermo Fisher Scientific medical and scientific leadership. The committee selects awardees based on the scientific merit of the proposed project.



Submission is done by sending the proposal form to the following email address: medical.affairs@thermofisher.com or using the [online grant management portal](#).

Submissions are confirmed by the grant office via email. Decisions are communicated 6–8 weeks after the closing date of the call.

Upon contract signature, the requested support will be granted. The grant office team will continue to support the development of the awarded project. A final report is due to the grant office team within the agreed time frame.

“In the long term, our goal is to promote equity of access to molecular profiling in cancer research and further democratize the future of precision medicine.”

—Dr. José Luís Costa
Director, OncoMine Clinical Research Grant Program
Thermo Fisher Scientific

2026 program details and deadlines

We welcome applications from laboratories of any size and across all continents.

Now accepting applications for projects with a focus on:

Cancer genomic profiling

Application periods:

May 1–June 15, 2026

For detailed information about how to apply, including documentation requirements, the review process, and decision notification, refer to our [website](#).

 Learn more and apply at oncomine.com/grants

For Research Use Only. Not for use in diagnostic procedures. © 2023–2026 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. **BROC-14149415 0426**

* No purchase necessary. This program is open only to institutions and health care organizations that support research in the field of molecular testing in oncology and reproductive health (“Applicants”) who submit the Application (“Application”) located at oncomine.com/grants. Applications may not be submitted by individuals, though Applications may be prepared by individuals or employees of Applicants, including but not limited to the person(s) in charge of the scientific research (“Principal Investigator”). Government Officials (term defined in the complete terms and conditions) may not participate in this program. Applications must be received by Sponsor within the Application Period. Submitted Applications will be judged based on alignment with the Merit of the Project (MP) score. Winners will be selected to receive an amount that will vary depending on the number of Winners per Application Period. The maximum value awarded to a Winner for each Application Period is \$200,000. Sponsor reserves the right to cancel this program if a minimum number of 10 qualified submissions are not able to proceed to the judging stage. Participants warrant that they are not prohibited by employment, contract, or law from accepting an award from the Sponsor. Geographic restrictions apply. Offer void where prohibited, licensed, or restricted by federal, state, provincial, or local laws, regulations, or agency/institutional policies. Other restrictions may apply. In case of any inconsistency between these short rules and the complete terms and conditions, the complete terms and conditions will always prevail. A copy of the complete terms and conditions is available at oncomine.com/grants.

